ClinicalTrials.gg
RecruitingNCT07622706Updated Oct 27, 2026

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

A Phase 2 interventional study of Firmonertinib 80mg qd oral for 8 weeks. and Firmonertinib 160mg qd oral for 8 weeks. in NSCLC, EGFR Positive Non-small Cell Lung Cancer and Neoadjuvant Therapy, sponsored by Peking University Cancer Hospital & Institute. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Peking University Cancer Hospital & Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 27, 2026Now RecruitingFirst site in China+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
19th of 41
60 · median 60
Started
2026
with 8 others
Phase 2
26 of 41
22 open now
Primary completion
2029-12
later than 31 of 33 live
Registered
40th of 41
by date
Lead sponsor
3 of 41
Peking University Cancer Hospital & Institute

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by planned enrollment, is one of 9 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 31 of the 33 other live ones, and was the 40th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma.

The goal of this study was to evaluate the efficacy of firmonertinib neoadjuvant in patients with resectable stage II-IIIB EGFR-mutated non-small cell lung cancer (NSCLC) by major pathologic response (MPR).

03

Conditions studied

  • NSCLC
  • EGFR Positive Non-small Cell Lung Cancer
  • Neoadjuvant Therapy
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Prior to the initiation of any study-related procedures, including examinations, sample collection, or analyses, written was obtained from all participating patients.
  • 2.Male or female, aged >=18 years;
  • 3. or cytologically confirmed primary lung adenocarcinoma within 60 days prior to study entry.
  • 4.Stage II-IIIB disease (AJCC 9th edition) confirmed by systematic imaging (contrast-enhanced chest/abdominal CT, brain CT/MRI, bone scan, or PET/CT), with lesions eligible for radical resection.
  • 5.EGFR mutation-positive (19Del and/or L858R, with or without T790M) as determined by NGS testing of tumor tissue or blood.
  • 6.At least one with a longest diameter >=10 mm on baseline CT scan (except lymph nodes, which must have a short-axis diameter >=15 mm), and suitable for accurate and repeated measurement.
  • 7. performance status 0-1.
  • 8. Female patients should take adequate and effective , must not breastfeed, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to demonstrate infertility: (1) , defined as older than 50 years of age and having no menstruation for at least 12 months after stopping all exogenous hormone therapy. (2) For women under 50 years old, if there is no menstruation for 12 months or longer after stopping exogenous hormone therapy, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are in the postmenopausal range, they are considered postmenopausal. (3) Documented irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
  • 9. Male patients should be willing to use barrier contraception, i.e., condoms.

Exclusion criteria

Exclusion Criteria:

  • 1.Tumors with squamous cell carcinoma, large cell carcinoma, or neuroendocrine components such as small cell carcinoma.
  • 2.Presence of EGFR exon 20 insertion mutation detected by genetic testing.
  • 3.Prior exposure to other antitumor therapies before enrollment.
  • 4.Major surgery within 4 weeks prior to the first dose of study drug (including surgery for the primary tumor, excluding procedures for vascular access).
  • 5.Scheduled or planned medical procedures (e.g., endoscopy or ) or surgical operations within the next 4 months.
  • 6.The patient is pregnant or breastfeeding.
  • 7.Use of strong inhibitors within 7 days, or strong CYP3A4 inducers within 21 days prior to the first dose of study drug; use of traditional Chinese medicines or herbal preparations indicated for antitumor treatment, those with tumor adjuvant effects, or any other agents with known antitumor activity within 14 days prior to the first dose.
  • 8.History of other or concurrent malignancies, except for those that have been definitively treated with curative intent and with no evidence of recurrence for at least 5 years (e.g., carcinoma in situ of the cervix, basal cell carcinoma of the skin, or papillary thyroid carcinoma).
  • 9.Patients with severe or uncontrolled systemic diseases requiring treatment, deemed unsuitable for participation by the investigator. These include but are not limited to: uncontrolled hypertension, diabetes, chronic heart failure ( class III-IV), unstable angina, myocardial infarction within the past year, active bleeding disorders; (including all HBsAg-positive patients), (HCV antibody positive), or (HIV) infection; as well as patients with active infections requiring intravenous treatment.
  • 10.Patients with severe gastrointestinal dysfunction or clinical conditions that may affect the intake, transport, or absorption of the study drug, such as inability to take oral medication, uncontrolled nausea and vomiting, or a history of extensive gastrointestinal resection.
  • 11. Meets any of the following cardiac assessment criteria: (1) Resting interval (QTc) >470 msec, with QTc corrected using the Fridericia formula (if the initial ECG shows QTc >470 ms, repeat the ECG twice and take the average of the three QTc results). (2) Any abnormalities in heart rhythm, conduction, or morphology on resting ECG, such as complete left bundle branch block, second-degree or third-degree atrioventricular block, etc. (3) Any factors that increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, sudden unexplained death in first-degree relatives under 40 years old, or taking any concomitant medication known to prolong the QT interval that cannot be discontinued.
  • 12. History of interstitial lung disease (ILD), drug-induced interstitial lung disease, radiation pneumonitis requiring treatment, or patients with clinical manifestations suspected to be interstitial lung disease.
  • 13. Any of the following laboratory test results indicating insufficient bone marrow or organ reserve function: (1) \<1.5×10\^9/L; (2) count \<100×10\^9/L; (3) \<90 g/L; (4) (ALT) >2.5× (ULN); (5) Aspartate aminotransferase (AST) >2.5×ULN; (6) Total >1.5×ULN or, in the case of Gilbert's syndrome (unconjugated hyperbilirubinemia), >3×ULN; (7) \<50 mL/min (calculated by the Cockcroft-Gault formula); (8) (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT) >=1.5 times ULN;
  • 14. Known or suspected allergy to pralsetinib or any other component of its formulation;
  • 15. Other situations where the patient is unable to comply with study procedures, restrictions, or requirements, and the investigator considers that such patient should not or is unsuitable to participate in the study;
  • 16. Patients currently or previously participating in any other anti-tumor clinical study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A

    Participations will receive the drug treatments preoperatively. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Drug: Firmonertinib 80mg qd oral for 8 weeks. · Procedure: Radical resection · Drug: firmonertinib adjuvant therapy

  • Experimental
    Group B

    Participations will receive the drug treatments preoperatively. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Drug: Firmonertinib 160mg qd oral for 8 weeks. · Procedure: Radical resection · Drug: firmonertinib adjuvant therapy

  • Experimental
    Group C

    Participations will receive the drug treatments preoperatively. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Drug: Firmonertinib 80mg qd oral for 16 weeks. · Procedure: Radical resection · Drug: firmonertinib adjuvant therapy

Interventions

  • DrugAflutinibStudies of AflutinibAflutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Also known as: AST-2818

  • DrugAflutinibStudies of AflutinibAflutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participations will receive the drug treatments preoperatively: Firmonertinib 160mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Also known as: AST-2818

  • DrugAflutinibStudies of AflutinibAflutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 16 weeks. Radical tumor resection will be completed 3-4 weeks after the end of drug treatment.

    Also known as: AST-2818

  • ProcedureRadical resection

    Radical resection of the tumor will be performed within 3-4 weeks after the end of treatment.

  • DrugAflutinibStudies of AflutinibAflutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After surgery, participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral as adjuvant therapy for 3 years. The investigator may decide whether to add chemotherapy or to change other adjuvant treatment modalities.

    Also known as: AST-2818

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate

    Defined as the time from the date of surgery to the first occurrence of local or distant disease recurrence, or death from any cause.

    Time frame: At the time of surgery (approximately Week 12 from treatment initiation for Cohort 1 and Cohort 2, and Week 20 for Cohort 3), Assessed up to 3 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    The percentage of patients who achieve a Complete Response (CR) or Partial Response (PR) based on radiological evaluation (e.g., RECIST v1.1).

    Time frame: From baseline up to the pre-operative tumor assessment (at Week 8 for Cohort 1 and Cohort 2, and at Week 16 for Cohort 3). Assessed up to 3 years

  2. Disease Control Rate (DCR)

    The percentage of patients who achieve CR, PR, or Stable Disease (SD) based on radiological evaluation (e.g., RECIST v1.1).

    Time frame: From baseline up to the pre-operative tumor assessment (at Week 8 for Cohort 1 and Cohort 2, and at Week 16 for Cohort 3). Assessed up to 3 years

  3. Pathological Complete Response (pCR) Rate

    The proportion of patients with no remaining viable tumor cells (ypT0N0) in the resected primary tumor and sampled lymph nodes

    Time frame: From baseline up to the pre-operative tumor assessment (at Week 8 for Cohort 1 and Cohort 2, and at Week 16 for Cohort 3). Assessed up to 3 years

  4. R0 Resection Rate

    The percentage of patients who achieve radical tumor resection with microscopically negative margins (R0 resection) as confirmed by histopathological analysis.

    Time frame: At the time of surgery (approximately Week 12 from treatment initiation for Cohort 1 and Cohort 2, and Week 20 for Cohort 3) compared to baseline clinical staging. Assessed up to 3 years

  5. Pathological Lymph Node Downstaging Rate

    The proportion of patients who exhibit a reduction in pathological lymph node stage compared to their pre-treatment clinical staging

    Time frame: From baseline up to the pre-operative tumor assessment (at Week 8 for Cohort 1 and Cohort 2, and at Week 16 for Cohort 3). Assessed up to 3 years

  6. Disease-Free Survival (DFS)

    Defined as the time from the date of surgery to the first occurrence of local or distant disease recurrence, or death from any cause.

    Time frame: From the date of radical surgery up to the date of first documented disease recurrence or death from any cause, assessed up to 3.5 years

  7. Incidence and Severity of Adverse Events (AEs)

    The frequency, severity, and types of adverse events, graded and classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the first dose of study drug until 28 days after the last dose of study drug, and throughout the perioperative/adjuvant treatment period assessed up to 3.5 years

  8. Incidence of Surgical Complications

    The percentage and specific types of surgery-related complications reported in the perioperative phase.

    Time frame: Within 30 days following the surgical procedure assessed up to 3.5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 39 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start May 2026 → Sep 2026, primary completion May 2028 → Dec 2029 and completion Nov 2029 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Sep 3, 2026was May 2026
Primary completionEst.
Dec 30, 2029was May 2028
CompletionEst.
Dec 30, 2029was Nov 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in China
Show site
  • Peking University Cancer Hospital & Institute · Beijing, China
Oct 27, 2026
Start date
May 30, 2026→Sep 3, 2026 (actual)
Oct 27, 2026
Primary completion
May 30, 2028→Dec 30, 2029
Oct 27, 2026
Study completion
Nov 30, 2029→Dec 30, 2029
Oct 27, 2026
Eligibility
2 inclusion criteria edited, 2 added, 3 removed; 3 exclusion criteria edited, 6 added
What changed in the criteria
Inclusion criteria
  • Added2.Male or female, aged >=18 years;
  • Edited2.Male or female, aged >=18 years; 3.Histologically or cytologically confirmed primary lung adenocarcinoma within 60 days prior to study entry.
  • Removed7.ECOG performance status 0-1. 8. Female patients should take adequate and effective contraception, must not breastfeed, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to demonstrate infertility:
  • RemovedPostmenopausal, defined as older than 50 years of age and having no menstruation for at least 12 months after stopping all exogenous hormone therapy.
  • Added7.ECOG performance status 0-1.
  • Edited8. Female patients should take adequate and effective contraception, must not breastfeed, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to demonstrate infertility: (1) Postmenopausal, defined as older than 50 years of age and having no menstruation for at least 12 months after stopping all exogenous hormone therapy. (2) For women under 50 years old, if there is no menstruation for 12 months or longer after stopping exogenous hormone therapy, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are in the postmenopausal range, they are considered postmenopausal. (3) Documented irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
  • RemovedDocumented irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
Exclusion criteria
  • Added2.Presence of EGFR exon 20 insertion mutation detected by genetic testing.
  • Added3.Prior exposure to other antitumor therapies before enrollment.
  • Edited2.Presence of EGFR exon 20 insertion mutation detected by genetic testing. 3.Prior exposure to other antitumor therapies before enrollment. 4.Major surgery within 4 weeks prior to the first dose of study drug (including surgery for the primary tumor, excluding procedures for vascular access).
  • Added6.The patient is pregnant or breastfeeding.
  • Edited6.The patient is pregnant or breastfeeding. 7.Use of strong CYP3A4 inhibitors within 7 days, or strong CYP3A4 inducers within 21 days prior to the first dose of study drug; use of traditional Chinese medicines or herbal preparations indicated for antitumor treatment, those with tumor adjuvant effects, or any other agents with known antitumor activity within 14 days prior to the first dose.
  • Edited13. Any of the following laboratory test results indicating insufficient bone marrow or organ reserve function: (1) Absolute neutrophil count <1.5×10\^9/L; (2) Platelet count <100×10\^9/L; (3) Hemoglobin <90 g/L; (4) Alanine aminotransferase (ALT) >2.5× upper limit of normal (ULN); (5) Aspartate aminotransferase (AST) >2.5×ULN; (6) Total bilirubin >1.5×ULN or, in the case of Gilbert's syndrome (unconjugated hyperbilirubinemia), >3×ULN; (7) Creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); (8) Prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT) >=1.5 times ULN; 14. Known or suspected allergy to pralsetinib or any other component of its formulation; 15. Other situations where the patient is unable to comply with study procedures, restrictions, or requirements, and the investigator considers that such patient should not or is unsuitable to participate in the study; 16. Patients currently or previously participating in any other anti-tumor clinical study.
  • Added14. Known or suspected allergy to pralsetinib or any other component of its formulation;
  • Added15. Other situations where the patient is unable to comply with study procedures, restrictions, or requirements, and the investigator considers that such patient should not or is unsuitable to participate in the study;
  • Added16. Patients currently or previously participating in any other anti-tumor clinical study.
Oct 27, 2026
Interventions
Added Procedure: Radical resection·Drug: firmonertinib adjuvant therapy
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in China
    Show site
    • Peking University Cancer Hospital & Institute · Beijing, China
    Start date May 30, 2026→Sep 3, 2026 (now actual)
    Primary completion May 30, 2028→Dec 30, 2029
    Study completion Nov 30, 2029→Dec 30, 2029
    Eligibility 2 inclusion criteria edited, 2 added, 3 removed; 3 exclusion criteria edited, 6 added
    What changed in the criteria
    Inclusion criteria
    • Added2.Male or female, aged >=18 years;
    • Edited2.Male or female, aged >=18 years; 3.Histologically or cytologically confirmed primary lung adenocarcinoma within 60 days prior to study entry.
    • Removed7.ECOG performance status 0-1. 8. Female patients should take adequate and effective contraception, must not breastfeed, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to demonstrate infertility:
    • RemovedPostmenopausal, defined as older than 50 years of age and having no menstruation for at least 12 months after stopping all exogenous hormone therapy.
    • Added7.ECOG performance status 0-1.
    • Edited8. Female patients should take adequate and effective contraception, must not breastfeed, and have a negative pregnancy test before the first administration of the study drug; or female patients must meet the following criteria at screening to demonstrate infertility: (1) Postmenopausal, defined as older than 50 years of age and having no menstruation for at least 12 months after stopping all exogenous hormone therapy. (2) For women under 50 years old, if there is no menstruation for 12 months or longer after stopping exogenous hormone therapy, and luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are in the postmenopausal range, they are considered postmenopausal. (3) Documented irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
    • RemovedDocumented irreversible sterilization surgery, including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, excluding tubal ligation.
    Exclusion criteria
    • Added2.Presence of EGFR exon 20 insertion mutation detected by genetic testing.
    • Added3.Prior exposure to other antitumor therapies before enrollment.
    • Edited2.Presence of EGFR exon 20 insertion mutation detected by genetic testing. 3.Prior exposure to other antitumor therapies before enrollment. 4.Major surgery within 4 weeks prior to the first dose of study drug (including surgery for the primary tumor, excluding procedures for vascular access).
    • Added6.The patient is pregnant or breastfeeding.
    • Edited6.The patient is pregnant or breastfeeding. 7.Use of strong CYP3A4 inhibitors within 7 days, or strong CYP3A4 inducers within 21 days prior to the first dose of study drug; use of traditional Chinese medicines or herbal preparations indicated for antitumor treatment, those with tumor adjuvant effects, or any other agents with known antitumor activity within 14 days prior to the first dose.
    • Edited13. Any of the following laboratory test results indicating insufficient bone marrow or organ reserve function: (1) Absolute neutrophil count <1.5×10\^9/L; (2) Platelet count <100×10\^9/L; (3) Hemoglobin <90 g/L; (4) Alanine aminotransferase (ALT) >2.5× upper limit of normal (ULN); (5) Aspartate aminotransferase (AST) >2.5×ULN; (6) Total bilirubin >1.5×ULN or, in the case of Gilbert's syndrome (unconjugated hyperbilirubinemia), >3×ULN; (7) Creatinine clearance <50 mL/min (calculated by the Cockcroft-Gault formula); (8) Prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT) >=1.5 times ULN; 14. Known or suspected allergy to pralsetinib or any other component of its formulation; 15. Other situations where the patient is unable to comply with study procedures, restrictions, or requirements, and the investigator considers that such patient should not or is unsuitable to participate in the study; 16. Patients currently or previously participating in any other anti-tumor clinical study.
    • Added14. Known or suspected allergy to pralsetinib or any other component of its formulation;
    • Added15. Other situations where the patient is unable to comply with study procedures, restrictions, or requirements, and the investigator considers that such patient should not or is unsuitable to participate in the study;
    • Added16. Patients currently or previously participating in any other anti-tumor clinical study.
    Interventions Added Procedure: Radical resection·Drug: firmonertinib adjuvant therapy
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07622706
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Sep 3, 2026
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Jia Wang, proffessor
Contact
gcp_yuanyn@bjcancer.org
86-10-88196391

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflutinib

Start the discussion